Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

[1] Heeringa J(2006)Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J. 27 949-53

[2] van der Kuip DAM(2006)ACC/AHA/ESC 2006. Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001. Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circ

[3] Hofman A(2013)Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people Arch Cardiovasc Dis. 106 303-23

[4] Fuster V(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med. 146 857-67

[5] Ryden LE(2011)Emergency hospitalizations for adverse drug events in older Americans N Engl J Med. 365 2002-12

[6] Cannom DS(2002)Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention Intern Med J. 32 15-23

[7] Hanon O(2015)Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort J Nutr Health Aging. 19 219-27

[8] Assayag P(2010)Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med. 123 638-645

[9] Belmin J(2014)Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials Lancet. 383 955-62

[10] Hart RG(2015)Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis Circulation. 132 194-204

[1] Heeringa J(2006)Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J. 27 949-53

[2] van der Kuip DAM(2006)ACC/AHA/ESC 2006. Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001. Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circ

[3] Hofman A(2013)Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people Arch Cardiovasc Dis. 106 303-23

[4] Fuster V(2007)Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med. 146 857-67

[5] Ryden LE(2011)Emergency hospitalizations for adverse drug events in older Americans N Engl J Med. 365 2002-12

[6] Cannom DS(2002)Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention Intern Med J. 32 15-23

[7] Hanon O(2015)Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort J Nutr Health Aging. 19 219-27

[8] Assayag P(2010)Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med. 123 638-645

[9] Belmin J(2014)Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials Lancet. 383 955-62

[10] Hart RG(2015)Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis Circulation. 132 194-204